• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    ICL And Lavie Bio Leverage AI To Make Significant Advancement In Development Of Yield Increasing Bio-Stimulants

    7/17/24 8:03:34 AM ET
    $EVGN
    $ICL
    Agricultural Chemicals
    Industrials
    Agricultural Chemicals
    Industrials
    Get the next $EVGN alert in real time by email

    More than one dozen novel microbes identified for row crops suffering from extreme weather conditions

    TEL AVIV and REHOVOT, Israel, July 17, 2024 /PRNewswire/ -- ICL (NYSE:ICL) (TASE: ICL), a leading global specialty minerals company, and Lavie Bio Ltd., a leading ag-biologicals company and subsidiary of Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), today announced a significant milestone in their collaboration to develop bio-stimulant solutions for key row crops facing various abiotic stresses. By leveraging artificial intelligence (AI), Lavie Bio has computationally identified more than a dozen novel microbial candidates believed to have commercial viability as bio-stimulants for crops grown under extreme weather conditions, including drought.  While this process can normally take several years, the collaboration achieved success within its first 12 months – thanks to Lavie Bio's proprietary Biology Driven Design (BDD) technology platform.

    Get the next $EVGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EVGN
    $ICL

    CompanyDatePrice TargetRatingAnalyst
    ICL Group Ltd.
    $ICL
    1/21/2025$4.00 → $6.00Underweight → Equal Weight
    Barclays
    ICL Group Ltd.
    $ICL
    1/12/2024$6.50 → $4.00Overweight → Underweight
    Barclays
    ICL Group Ltd.
    $ICL
    11/14/2023$7.00 → $6.50Equal Weight → Overweight
    Barclays
    ICL Group Ltd.
    $ICL
    5/18/2023Buy → Neutral
    BofA Securities
    ICL Group Ltd.
    $ICL
    6/1/2022$12.00Equal Weight
    Barclays
    ICL Group Ltd.
    $ICL
    2/14/2022$9.00 → $10.00Equal-Weight
    Morgan Stanley
    ICL Group Ltd.
    $ICL
    12/6/2021$7.00 → $9.00Equal-Weight
    Morgan Stanley
    Evogene Ltd
    $EVGN
    11/24/2021$8.00 → $7.00Outperform
    RBC Capital
    More analyst ratings

    $EVGN
    $ICL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ICL Group upgraded by Barclays with a new price target

    Barclays upgraded ICL Group from Underweight to Equal Weight and set a new price target of $6.00 from $4.00 previously

    1/21/25 7:50:33 AM ET
    $ICL
    Agricultural Chemicals
    Industrials

    ICL Group downgraded by Barclays with a new price target

    Barclays downgraded ICL Group from Overweight to Underweight and set a new price target of $4.00 from $6.50 previously

    1/12/24 6:56:19 AM ET
    $ICL
    Agricultural Chemicals
    Industrials

    ICL Group upgraded by Barclays with a new price target

    Barclays upgraded ICL Group from Equal Weight to Overweight and set a new price target of $6.50 from $7.00 previously

    11/14/23 7:37:49 AM ET
    $ICL
    Agricultural Chemicals
    Industrials

    $EVGN
    $ICL
    SEC Filings

    View All

    SEC Form D filed by Evogene Ltd

    D - Evogene Ltd. (0001574565) (Filer)

    2/19/26 4:01:05 PM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    SEC Form 6-K filed by ICL Group Ltd.

    6-K - ICL Group Ltd. (0000941221) (Filer)

    2/18/26 6:05:17 AM ET
    $ICL
    Agricultural Chemicals
    Industrials

    SEC Form 6-K filed by ICL Group Ltd.

    6-K - ICL Group Ltd. (0000941221) (Filer)

    2/18/26 6:00:54 AM ET
    $ICL
    Agricultural Chemicals
    Industrials

    $EVGN
    $ICL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Evogene Schedules Fourth Quarter and Full Year 2025 Financial Results Release

    Zoom conference call scheduled for March 5, 2026, 9:00 AM ET REHOVOT, Israel, Feb. 19, 2026 /PRNewswire/ -- Evogene Ltd . (NASDAQ:EVGN) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, announced today that it will release its financial results for the fourth quarter and full year 2025, on Thursday, March 5, 2026. Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time).To attend the conference, please register in advance: https://www.veidan-conferencing.com/evogene The entire conference will be

    2/19/26 8:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    ICL Reports Fourth Quarter and Full Year 2025 Results

    Annual sales increase 5% to $7,153 million, with adjusted EBITDA of $1,488 million and earnings per share of $0.36 Company advances strategic principles, with acquisition of Bartek Ingredients and review of non-core assets ICL (NYSE:ICL) (TASE: ICL), a leading global specialty minerals company, today reported its financial results for the fourth quarter and full year ended December 31, 2025. For the fourth quarter, consolidated sales of $1,701 million were up 6% versus $1,601 million in the fourth quarter of 2024. Operating income was ($16) million versus $147 million, while adjusted operating income of $223 million was up 17% versus $190 million in 2024. Adjusted EBITDA of $380 million

    2/18/26 2:15:00 AM ET
    $ICL
    Agricultural Chemicals
    Industrials

    Evogene and Queensland University of Technology (QUT) Announce a Collaboration to Advance AI-Driven Cancer Therapeutics

    Aiming to introduce a new therapeutic strategy for overcoming chemotherapy resistance in lung cancer due to increased expression of cellular pathwaysREHOVOT, Israel, Feb. 17, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in the generative design of small molecules for the pharmaceutical and agricultural industries today announced a collaboration with the pioneering research group of Dr. Mark Adams, a leading cancer genomics expert in the School of Biomedical Sciences and Faculty of Health at the Queensland University of Technology (QUT), Australia. This partnership aims to accelerate the discovery and optimization of n

    2/17/26 8:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    $EVGN
    $ICL
    Leadership Updates

    Live Leadership Updates

    View All

    Evogene, Systasy and LMU University Hospital Munich Announce a Collaboration to Develop Novel Therapies for Neutrophil-Derived Inflammatory Diseases

    The collaboration is supported by a pan-European EUREKA grant, with participation of the Weizmann Institute of Science REHOVOT, Israel and MUNICH, Germany, Feb. 11, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, Systasy Bioscience GmbH, a biotechnology company leveraging proprietary DNA barcoding technology for hyper-multiplexed pathway profiling in patient-derived iPSC models to accelerate drug discovery for complex disorders, and LMU University Hospital Munich, today announced a collaboration aiming to accelerate the devel

    2/11/26 8:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    Evogene Appoints Prof. John Irwin and Prof. Dan Major to its Scientific Advisory Board

    Appointments Strengthen Scientific Leadership and Support the Acceleration of ChemPass AI™ for Drug and Ag-Chemical Discovery REHOVOT, Israel, Feb. 9, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational chemistry company focused on the AI-driven discovery and design of novel small molecules for the pharmaceutical and agricultural industries, today announced the appointment of Prof. John J. Irwin of the University of California, San Francisco (UCSF), and Prof. Dan T. Major of Bar-Ilan University (BIU) to its scientific advisory board (SAB). The

    2/9/26 8:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    Evogene Announces Appointment of Dr. Olga Nissan as its Vice President of Business Development

    REHOVOT, Israel, Dec. 30, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, is pleased to announce the appointment of Dr. Olga Nissan as its Vice President of Business Development, effective as of January 1, 2026. Dr. Nissan is a seasoned biotechnology and pharmaceutical executive with extensive experience in bridging science, business, and funding. She has a proven track record of leading R&D, clinical develop

    12/30/25 7:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    $EVGN
    $ICL
    Financials

    Live finance-specific insights

    View All

    Evogene Schedules Fourth Quarter and Full Year 2025 Financial Results Release

    Zoom conference call scheduled for March 5, 2026, 9:00 AM ET REHOVOT, Israel, Feb. 19, 2026 /PRNewswire/ -- Evogene Ltd . (NASDAQ:EVGN) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, announced today that it will release its financial results for the fourth quarter and full year 2025, on Thursday, March 5, 2026. Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time).To attend the conference, please register in advance: https://www.veidan-conferencing.com/evogene The entire conference will be

    2/19/26 8:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    ICL Reports Fourth Quarter and Full Year 2025 Results

    Annual sales increase 5% to $7,153 million, with adjusted EBITDA of $1,488 million and earnings per share of $0.36 Company advances strategic principles, with acquisition of Bartek Ingredients and review of non-core assets ICL (NYSE:ICL) (TASE: ICL), a leading global specialty minerals company, today reported its financial results for the fourth quarter and full year ended December 31, 2025. For the fourth quarter, consolidated sales of $1,701 million were up 6% versus $1,601 million in the fourth quarter of 2024. Operating income was ($16) million versus $147 million, while adjusted operating income of $223 million was up 17% versus $190 million in 2024. Adjusted EBITDA of $380 million

    2/18/26 2:15:00 AM ET
    $ICL
    Agricultural Chemicals
    Industrials

    ICL Announces Fourth Quarter 2025 Earnings Call

    ICL (NYSE:ICL) (TASE: ICL), a leading global specialty minerals company, today announced it plans to release fourth quarter 2025 results prior to the opening of the TASE market on Wednesday, February 18, 2026. On that day, Elad Aharonson, president and CEO of ICL, and Aviram Lahav, CFO of ICL, will host a conference call to discuss results, provide a general business update and answer questions at 8:30 a.m. New York time (1:30 p.m. London and 3:30 p.m. Tel Aviv). The dial-in number for financial analysts in North America is (800) 549-8228, or (289) 819-1520 for international analysts, and the conference ID is 71097. To participate, please dial in a few minutes before the scheduled time.

    1/29/26 8:30:00 AM ET
    $ICL
    Agricultural Chemicals
    Industrials

    $EVGN
    $ICL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ICL Group Ltd.

    SC 13G/A - ICL Group Ltd. (0000941221) (Subject)

    11/14/24 6:11:02 AM ET
    $ICL
    Agricultural Chemicals
    Industrials

    Amendment: SEC Form SC 13G/A filed by Evogene Ltd

    SC 13G/A - Evogene Ltd. (0001574565) (Subject)

    10/15/24 6:52:26 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    SEC Form SC 13G filed by Evogene Ltd

    SC 13G - Evogene Ltd. (0001574565) (Subject)

    2/14/24 8:30:01 PM ET
    $EVGN
    Agricultural Chemicals
    Industrials